Hims & Hers Health, Inc.
HIMS · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 526.92M | 408.72M | -68.70M | -65.68M | -0.32 |
| 2023 FY | 872.00M | 714.95M | -29.45M | -23.55M | -0.11 |
| 2024 FY | 1.48B | 1.17B | 61.90M | 126.04M | 0.58 |
| 2025 FY | 2.35B | 1.73B | 105.61M | 128.37M | 0.57 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 366.34M | 54.60M | 46.77M | 5.31M | 311.74M |
| 2023 FY | 441.19M | 97.16M | 96.66M | 9.95M | 344.03M |
| 2024 FY | 707.54M | 230.82M | 220.58M | 11.35M | 476.72M |
| 2025 FY | 2.15B | 1.61B | 228.62M | 1.12B | 540.93M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -26.53M | -7.25M | -33.78M | — | -25.01M |
| 2023 FY | 73.48M | -26.49M | 46.99M | — | 49.89M |
| 2024 FY | 251.08M | -52.75M | 198.33M | — | 123.92M |
| 2025 FY | 300.01M | -226.05M | 73.96M | — | 8.03M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 1.31B | 1.27B | — | — | — |
| 2023 FY | 1.86B | 1.78B | — | — | — |
| 2024 FY | 5.22B | 5.01B | — | — | — |
| 2025 FY | 7.30B | 8.20B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 544.83M | 416.20M | 26.72M | 42.51M | 0.19 |
| 2025 Q3 | 598.98M | 442.06M | 11.81M | 15.77M | 0.07 |
| 2025 Q4 | 617.82M | 444.44M | 9.19M | 20.60M | 0.09 |
| 2026 Q1 | 608.10M | 300.28M | -16.47M | -92.12M | -0.40 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.88B | 1.31B | 1.12B | 1.04B | 562.70M |
| 2025 Q3 | 2.23B | 1.65B | 345.78M | 1.12B | 580.98M |
| 2025 Q4 | 2.15B | 1.61B | 228.62M | 1.12B | 540.93M |
| 2026 Q1 | 2.27B | 1.82B | 222.27M | 1.13B | 446.17M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -19.12M | -50.32M | -69.43M | — | 849.99M |
| 2025 Q3 | 148.72M | -57.30M | 91.42M | — | -779.17M |
| 2025 Q4 | 64.70M | -63.88M | 821.00K | — | -117.16M |
| 2026 Q1 | 89.36M | -36.32M | 53.03M | — | -6.35M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 11.19B | 11.10B | — | — | — |
| 2025 Q3 | 12.84B | 13.61B | — | — | — |
| 2025 Q4 | 7.37B | 8.26B | — | — | — |
| 2026 Q1 | 4.74B | 5.65B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |